FDA-backed CBD drug brings in $296 million in 'incredible launch year,' GW Pharma CEO says. "It's an incredible launch year for any medication [that] I think proves that this kind of medicine is really making a difference to patients," GW Pharma CEO Justin Gover said after selling $296 million worth of Epidiolex in 2019.
"It shows real value to the health-care system, and it sets us up, I think, in a very nice way for what should be another great year for us in 2020," he said in a "Mad Money" interview.
Epidiolex is the first CBD-based epilepsy treatment launched in the United States. #cbdfollow @cbdfollow for the latest in CBD retail news. - 3 minutes ago